|
Mit der Zulassung von Tramadol in den USA wäre die Zukunkft von Labopharm so gut wie gesichert. Und da ist noch Trazadone das auch schon bald den Markt erreicht . Tramadol Potential The number of prescriptions written for tramadol products in the United States – the single largest market for tramadol – has more than doubled in the last decade, surpassing 21 million in 2006. The vast majority of these were for multiple dose products that must be taken anywhere from four- to six-times per day. Dollar sales related to these prescriptions was in excess of US$635 million. The potential market for a once-daily tramadol treatment, however, is considerably larger. Compliance with multiple-times daily dosing regimens can be challenging for patients, potentially limiting the efficacy of a drug. A once-daily formulation of tramadol offers significant value and satisfaction to both patients and physicians through the potential to improve compliance. Overall, the market for tramadol is expected to experience continued strong growth, driven primarily by three factors: As an opioid with additional unique mechanisms of action, tramadol is an excellent option in the treatment of moderate to moderately severe pain, providing effective pain relief without many of the potential side effects seen with stronger opioids; Tramadol is often prescribed for pain related to conditions that become more prevalent with age, such as osteoarthritis. The aging of the world’s population will precipitate a higher demand for therapeutics such as tramadol that address these age-related conditions; Third, in recent years, the U.S. pain market has become underserved as physicians and patients have eschewed certain classes of analgesics due to safety concerns. |
|
| aus der Diskussion: | Labopharm ....Nur geschenkt ist noch billiger |
| Autor (Datum des Eintrages): | BrauchGeld (07.06.08 21:58:24) |
| Beitrag: | 6 von 324 (ID:34261656) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |